Multicenter Automatic Defibrillator Implantation Trial-Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD): Design and clinical protocol
Valentina Kutyifa, Christopher Beck, Mary W Brown, David Cannom, James Daubert, Mark Estes, Henry Greenberg, Ilan Goldenberg, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Mikhail Kosiborod, Jeanne Poole, Claudio Schuger, Jagmeet P Singh, Scott Solomon, David Wilber, Wojciech Zareba, Arthur J Moss, MADIT S-ICD Executive Committee, Valentina Kutyifa, Christopher Beck, Mary W Brown, David Cannom, James Daubert, Mark Estes, Henry Greenberg, Ilan Goldenberg, Stephen Hammes, David Huang, Helmut Klein, Reinoud Knops, Mikhail Kosiborod, Jeanne Poole, Claudio Schuger, Jagmeet P Singh, Scott Solomon, David Wilber, Wojciech Zareba, Arthur J Moss, MADIT S-ICD Executive Committee
Abstract
Patients with diabetes mellitus, prior myocardial infarction, older age, and a relatively preserved left ventricular ejection fraction remain at risk for sudden cardiac death that is potentially amenable by the subcutaneous implantable cardioverter defibrillator with a good risk-benefit profile. The launched MADIT S-ICD study is designed to test the hypothesis that post-myocardial infarction diabetes patients with relatively preserved ejection fraction of 36%-50% will have a survival benefit from a subcutaneous implantable cardioverter defibrillator.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.
Source: PubMed